| Title | Optimizing hormone therapy for breast cancer: Translating gains to the early-stage setting. |
| Publication Type | Journal Article |
| Year of Publication | 2022 |
| Authors | A Chien, J, Kyalwazi, B, Esserman, LJ |
| Journal | Cell Rep Med |
| Volume | 3 |
| Issue | 6 |
| Pagination | 100664 |
| Date Published | 2022 Jun 21 |
| ISSN | 2666-3791 |
| Keywords | Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Hormones, Humans, Receptor, ErbB-2, Receptors, Estrogen, Receptors, Progesterone |
| Abstract | First-line CDK4/6 inhibitor ribociclib plus letrozole improves survival in the metastatic setting, but lack of accrual of African American women is a shortcoming. Predicting benefit in the early-stage setting and diverse enrollment in trials need to be priorities.. |
| DOI | 10.1016/j.xcrm.2022.100664 |
| Alternate Journal | Cell Rep Med |
| PubMed ID | 35732146 |
| PubMed Central ID | PMC9245052 |
